3篇
您的检索式：作者名="Jessica Audrey"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Radiotherapy for pleomorphic adenoma显示文摘 | AUDREY S W CHRISTOPHER G M JESSICA M K | 2013 | Ame J Otolaryngol2013，34，： | 1 |
| 2 | 先天性心脏病患儿父母心理韧性与社会人口学因素的关联性研究显示文摘目的研究先天性心脏病患儿父母的心理韧性,并调查可能的社会人口学影响因素。方法采用横断面研究设计,基于网络进行调查研究。采用目的抽样法招募515名作为先天性心脏病患儿主要照顾者的父母参与此项研究。使用特质心理韧性量表Ⅱ(Dispositional Resilience Scale-Ⅱ)评估患儿父母的韧性;基于专家访谈设计社会人口学资料问卷,收集患儿父母的社会人口学资料。采用描述性统计方法和多元线性回归分析对数据进行分析。结果共有413名患儿父母完成网络调查,心理韧性得分平均为3.75分(SD=0.61;范围1.89~4.89),得分越高,表明心理韧性越好。多元线性回归分析结果表明,患儿父母受教育程度越低,家庭收入越低,其心理韧性水平越低(P<0.05)。结论先天性心脏病患儿父母的心理韧性得分反映了他们应对压力事件的能力,以及对生育和照顾先天性心脏病患儿相关压力的缓和能力。护理实践和护士主导的干预应针对存在较低心理韧性水平风险的父母进行筛查并提供支持。由于较低的教育水平和经济困难很难通过个人努力加以改变,慈善基金会、联邦和州政府应考虑为这类患儿父母提供财务和健康知识支持的项目。 | Amy E.Delaney Mei Rosemary Fu Melissa L.McTernan Audrey C.Marshall Jessica Lindberg Ravi R.Thiagarajan Zhuzhu Zhou Jeibei Luo Sharon Glazer | 2022 | International Journal of Nursing Sciences2022，9，3： | 0 |
| 3 | Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori:Current perspectives and implications显示文摘Yu et al’s study in the World Journal of Gastroenterology(2023)introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii(S.boulardii)for the rescue therapy against Helicobacter pylori(H.pylori),a pathogen responsible for peptic ulcers and gastric cancer.Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression,which is minimally affected by mealtime.Compared to proton pump inhibitors,which bind irreversibly to cysteine residues in the H+/K+-ATPase pump,Vonoprazan competes with the K+ions,prevents the ions from binding to the pump and blocks acid secretion.Concerns with increasing antibiotic resistance,effects on the gut microbiota,patient compliance,and side effects have led to the advent of a dual regimen for H.pylori.Previous studies suggested that S.boulardii plays a role in stabilizing the gut barrier which improves H.pylori eradication rate.With an acceptable safety profile,the dual-adjunct regimen was effective regardless of prior treatment failure and antibiotic resistance profile,thereby strengthening the applicability in clinical settings.Nonetheless,S.boulardii comes in various formulations and dosages,warranting further exploration into the optimal dosage for supplementation in rescue therapy.Additionally,larger,randomized,double-blinded controlled trials are warranted to confirm these promising results. | Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata | 2024 | World Journal of Gastroenterology2024，30，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员